Cristina Fernández-Fernández
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cristina Fernández-Fernández has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Araceli Nuñez Ventura
Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department, Spanish Agency of Medicines and Medical Devices (AEMPS), Madrid, Spain
2 shared publications - María Gordillo-Marañón
Division of Real‐World Data and Pharmacoepidemiology, Medicines for Human Use Department Spanish Agency of Medicines and Medical Devices (AEMPS) Madrid Spain
2 shared publications - María del Mar Gutiérrez-Lobón
Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department, Spanish Agency of Medicines and Medical Devices (AEMPS), Madrid, Spain
2 shared publications - Nuria Sols Cueto
Agencia Española de Medicamentos y Productos Sanitarios
2 shared publications Araceli Núñez Ventura
Pharmacoepidemiology and Pharmacovigilance Division, Medicines for Human Use Department, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain
1 shared publicationD. Montero Corominas
División de Farmacoepidemiología y Farmacovigilancia, Departamento de Medicamentos de uso Humano, Agencia Española de Medicamentos y Productos Sanitarios, Calle Campezo 1, Edificio 8, 28022, Madrid, Spain
1 shared publication
Latest Publications
- 18 November 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (12)
Follow‐Up Questionnaires in Pharmacovigilance: A Quantitative Evaluation Based on Completeness Score
Purpose: Follow‐up questionnaires (FUQs) are routinely used in pharmacovigilance to gather further information on suspected adverse drug reactions (ADRs) and are frequently included within Risk Management Plans. However, despite their extensive use and regulatory relevance, their contribution to improving the quality and completeness of case reports has not previously been evaluated quantitatively. The objective of this study was to assess whether the recommendation to implement or discontinue a FUQ was associated with changes in the completeness of information in case reports. Methods: The minutes from January 2018 to July 2025 from the European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) were screened to identify recommendations regarding FUQ implementation or discontinuation. For active substance‐ADR combinations associated with a FUQ recommendation, case reports and a standardised measure of report completeness were obtained from EudraVigilance and VigiBase, the WHO global database of adverse event reports for medicines and vaccines, respectively. Interrupted time series analyses were conducted to assess the effect of specific FUQs on the quality of case reporting. Results: Across the 27 active substance‐ADR combinations evaluated, the impact of FUQs on report completeness was heterogeneous. Only six combinations showed statistically significant trend changes, of which one demonstrated a small improvement in completeness after FUQ implementation and five showed declining trends following implementation ( n = 1) or discontinuation ( n = 4). Conclusions: The present findings do not support a consistent association between FUQ implementation and improved case completeness. Other factors, including ADR‐related characteristics and heterogeneity in pharmacovigilance data collection practices, may be more important determinants of report quality. These findings provide the first quantitative evidence on FUQ effectiveness and support a more evidence‐based approach to their evaluation within pharmacovigilance systems.
- 18 November 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (12)
Follow‐Up Questionnaires in Pharmacovigilance: A Quantitative Evaluation Based on Completeness Score
Purpose: Follow‐up questionnaires (FUQs) are routinely used in pharmacovigilance to gather further information on suspected adverse drug reactions (ADRs) and are frequently included within Risk Management Plans. However, despite their extensive use and regulatory relevance, their contribution to improving the quality and completeness of case reports has not previously been evaluated quantitatively. The objective of this study was to assess whether the recommendation to implement or discontinue a FUQ was associated with changes in the completeness of information in case reports. Methods: The minutes from January 2018 to July 2025 from the European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) were screened to identify recommendations regarding FUQ implementation or discontinuation. For active substance‐ADR combinations associated with a FUQ recommendation, case reports and a standardised measure of report completeness were obtained from EudraVigilance and VigiBase, the WHO global database of adverse event reports for medicines and vaccines, respectively. Interrupted time series analyses were conducted to assess the effect of specific FUQs on the quality of case reporting. Results: Across the 27 active substance‐ADR combinations evaluated, the impact of FUQs on report completeness was heterogeneous. Only six combinations showed statistically significant trend changes, of which one demonstrated a small improvement in completeness after FUQ implementation and five showed declining trends following implementation ( n = 1) or discontinuation ( n = 4). Conclusions: The present findings do not support a consistent association between FUQ implementation and improved case completeness. Other factors, including ADR‐related characteristics and heterogeneity in pharmacovigilance data collection practices, may be more important determinants of report quality. These findings provide the first quantitative evidence on FUQ effectiveness and support a more evidence‐based approach to their evaluation within pharmacovigilance systems.
- 21 September 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (10) , 254
Masking effect in the Spanish spontaneous reporting database FEDRA
- 21 September 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (10) , 254
Masking effect in the Spanish spontaneous reporting database FEDRA
- Open Access
- 7 January 2026
- Published by Springer Nature in Drug Safety
- Vol. 49 (5) , 581-590
Evaluating COVID-19 Vaccine Masking and Unmasking Methods in Two National Pharmacovigilance Databases
Background The COVID-19 mass vaccination led to a substantial increase in spontaneous reports submitted to pharmacovigilance (PV) databases, potentially introducing masking effects that could conceal safety signals. Objectives To examine the masking effect of COVID-19 vaccines on disproportionality analyses and to compare two unmasking interventions in the Dutch (Lareb database) and Spanish (Farmacovigilancia Española, Datos de Reacciones Adversas, FEDRA) national PV databases: removal of all drug–event combinations (DEC) involving a COVID-19 vaccine versus excluding influential outliers DECs only. Methods The masking effect was explored retrospectively on the basis of the number of signals of disproportionate reporting (SDR). DECs involving a COVID-19 vaccine were excluded using crude and outlier techniques, and reporting odds ratios were recalculated. Subsets of important medical events (IME) were analysed in both databases. Results Both crude and influential outlier removal methods led to reductions in the number of reports, DECs and SDRs. Both in the Lareb database and FEDRA, crude removal excluded 2.1% of DECs, while the outlier method excluded 0.1%. Crude removal had a greater impact on SDRs, reducing them by 9.8% in the Lareb database and 3.9% in FEDRA, compared with 5.7% and 1.1% with the outlier method. In the Lareb database, 1301 SDRs (20 IME-related) were unmasked using crude removal, and 1942 (95 IME-related) with the outlier method. FEDRA showed 1453 and 1226 SDRs unmasked, including 41 and 70 IME-related. Conclusions COVID-19 vaccines caused substantial masking in both databases. Both strategies effectively revealed new SDRs, though their impact varied. The choice of approach should be tailored to the database context.
- 7 January 2026
- Published by Springer Nature in Drug Safety
- Vol. 49 (5) , 581-590
Open AccessEvaluating COVID-19 Vaccine Masking and Unmasking Methods in Two National Pharmacovigilance Databases
Background The COVID-19 mass vaccination led to a substantial increase in spontaneous reports submitted to pharmacovigilance (PV) databases, potentially introducing masking effects that could conceal safety signals. Objectives To examine the masking effect of COVID-19 vaccines on disproportionality analyses and to compare two unmasking interventions in the Dutch (Lareb database) and Spanish (Farmacovigilancia Española, Datos de Reacciones Adversas, FEDRA) national PV databases: removal of all drug–event combinations (DEC) involving a COVID-19 vaccine versus excluding influential outliers DECs only. Methods The masking effect was explored retrospectively on the basis of the number of signals of disproportionate reporting (SDR). DECs involving a COVID-19 vaccine were excluded using crude and outlier techniques, and reporting odds ratios were recalculated. Subsets of important medical events (IME) were analysed in both databases. Results Both crude and influential outlier removal methods led to reductions in the number of reports, DECs and SDRs. Both in the Lareb database and FEDRA, crude removal excluded 2.1% of DECs, while the outlier method excluded 0.1%. Crude removal had a greater impact on SDRs, reducing them by 9.8% in the Lareb database and 3.9% in FEDRA, compared with 5.7% and 1.1% with the outlier method. In the Lareb database, 1301 SDRs (20 IME-related) were unmasked using crude removal, and 1942 (95 IME-related) with the outlier method. FEDRA showed 1453 and 1226 SDRs unmasked, including 41 and 70 IME-related. Conclusions COVID-19 vaccines caused substantial masking in both databases. Both strategies effectively revealed new SDRs, though their impact varied. The choice of approach should be tailored to the database context.
- 20 December 2025
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (1) , 8
“Trends and challenges in adverse drug reaction reporting in Spain: Analysis of the FEDRA database (2019–2023)”
- 20 December 2025
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (1) , 8
“Trends and challenges in adverse drug reaction reporting in Spain: Analysis of the FEDRA database (2019–2023)”
- 23 May 2020
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (8) , 1175-1181
Quantity is not enough: completeness of suspected adverse drug reaction reports in Spain—differences between regional pharmacovigilance centres and pharmaceutical industry
Purpose The aim of this study is to compare the completeness of relevant structured fields such as age, sex, drug and reaction start dates, time to onset, outcome and drug indication, in serious spontaneous cases reported in Spain depending on whether they have been collected by regional pharmacovigilance centres or by the marketing authorization holders. Methods We analyzed the completeness of key variables for causality assessment related to the patient, the reaction and the suspected drug in all serious cases spontaneously reported and registered in the Spanish Pharmacovilance database, called FEDRA, from 1 January 2011 until 31 December 2018. The completeness scores were calculated according to the type of field and taking into account the VigiGrade tool. Cases were classified according to the reporting pathway, that is whether they were received and transmitted by marketing authorization holder or by regional pharmacovigilance centres. Results The completeness score of cases collected by regional pharmacovigilance centres was higher in all the studied variables. The main differences were found in drug and reaction start date, and time to onset. Conclusions This study shows a high completeness score in cases of suspected adverse reactions reported to the regional pharmacovigilance centres with regard to key elements for causality assessment, signal and duplicate detection. In contrast, marketing authorization holder cases show a low completeness score and a decreasing tendency in all the studied variables over the studied period.
- 23 May 2020
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (8) , 1175-1181
Quantity is not enough: completeness of suspected adverse drug reaction reports in Spain—differences between regional pharmacovigilance centres and pharmaceutical industry
Purpose The aim of this study is to compare the completeness of relevant structured fields such as age, sex, drug and reaction start dates, time to onset, outcome and drug indication, in serious spontaneous cases reported in Spain depending on whether they have been collected by regional pharmacovigilance centres or by the marketing authorization holders. Methods We analyzed the completeness of key variables for causality assessment related to the patient, the reaction and the suspected drug in all serious cases spontaneously reported and registered in the Spanish Pharmacovilance database, called FEDRA, from 1 January 2011 until 31 December 2018. The completeness scores were calculated according to the type of field and taking into account the VigiGrade tool. Cases were classified according to the reporting pathway, that is whether they were received and transmitted by marketing authorization holder or by regional pharmacovigilance centres. Results The completeness score of cases collected by regional pharmacovigilance centres was higher in all the studied variables. The main differences were found in drug and reaction start date, and time to onset. Conclusions This study shows a high completeness score in cases of suspected adverse reactions reported to the regional pharmacovigilance centres with regard to key elements for causality assessment, signal and duplicate detection. In contrast, marketing authorization holder cases show a low completeness score and a decreasing tendency in all the studied variables over the studied period.